10 Best Deeptech for November 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The 2025 equity landscape is shaped by rapid technological innovation, healthcare breakthroughs, and a renewed focus on sustainable energy. Our stock selection methodology leverages ValueSense’s proprietary intrinsic value tools, quality ratings, and sector diversification to identify companies with strong fundamentals, robust growth trajectories, and attractive valuations. Each stock is screened for financial health, growth potential, and sector relevance, ensuring a balanced and forward-looking watchlist[1][2].
Featured Stock Analysis
ASML Holding N.V. (ASML)
| Metric | Value |
|---|---|
| Market Cap | $410.6B |
| Quality Rating | 8.0 |
| Intrinsic Value | $861.0 |
| 1Y Return | 57.8% |
| Revenue | €32.2B |
| Free Cash Flow | €8,961.8M |
| Revenue Growth | 22.8% |
| FCF margin | 27.8% |
| Gross margin | 52.7% |
| ROIC | 30.2% |
| Total Debt to Equity | 14.2% |
Investment Thesis
ASML is the global leader in photolithography systems, essential for advanced semiconductor manufacturing. With a market cap of $410.6B and a stellar 1-year return of 57.8%, ASML’s dominance in extreme ultraviolet (EUV) technology positions it at the heart of the ongoing chip innovation cycle. The company’s €32.2B revenue and €8.96B free cash flow reflect both scale and operational excellence. Its 22.8% revenue growth and 52.7% gross margin underscore a durable competitive advantage, while a 30.2% ROIC signals efficient capital deployment.
Key Catalysts
- Sustained demand for advanced chips in AI, automotive, and cloud computing.
- Limited competition in EUV technology, creating high barriers to entry.
- Strong free cash flow supporting R&D and shareholder returns.
Risk Factors
- Geopolitical tensions affecting global chip supply chains.
- High customer concentration among leading chipmakers.
- Cyclical semiconductor demand patterns.
Ubiquiti Inc. (UI)
| Metric | Value |
|---|---|
| Market Cap | $47.6B |
| Quality Rating | 7.4 |
| Intrinsic Value | $156.6 |
| 1Y Return | 197.3% |
| Revenue | $2,573.5M |
| Free Cash Flow | $634.9M |
| Revenue Growth | 33.4% |
| FCF margin | 24.7% |
| Gross margin | 43.4% |
| ROIC | 85.8% |
| Total Debt to Equity | 44.5% |
Investment Thesis
Ubiquiti is a disruptor in wireless networking, delivering high-quality, cost-effective solutions for enterprise and consumer markets. With a $47.6B market cap and a remarkable 197.3% 1-year return, Ubiquiti’s growth is fueled by a 33.4% revenue increase and robust free cash flow of $634.9M. The company’s 43.4% gross margin and an exceptional 85.8% ROIC highlight operational efficiency and capital discipline. Its intrinsic value of $156.6 suggests continued upside as network infrastructure demand accelerates globally.
Key Catalysts
- Expansion in global wireless and IoT infrastructure.
- Strong brand loyalty and direct-to-consumer sales model.
- High-margin product portfolio driving profitability.
Risk Factors
- Competitive pressures from established networking giants.
- Supply chain vulnerabilities and component shortages.
- Elevated debt-to-equity ratio 44.5% compared to peers.
Nokia Oyj (NOK)
| Metric | Value |
|---|---|
| Market Cap | $37.3B |
| Quality Rating | 5.6 |
| Intrinsic Value | $7.6 |
| 1Y Return | 47.3% |
| Revenue | €19.8B |
| Free Cash Flow | €1,288.0M |
| Revenue Growth | 3.1% |
| FCF margin | 6.5% |
| Gross margin | 60.3% |
| ROIC | 5.5% |
| Total Debt to Equity | 20.7% |
Investment Thesis
Nokia remains a pivotal player in global telecommunications, focusing on 5G infrastructure and network solutions. With a $37.3B market cap and a 47.3% 1-year return, Nokia’s €19.8B revenue base and €1.29B free cash flow reflect steady operations. While revenue growth is modest at 3.1%, the company boasts a sector-leading 60.3% gross margin. Its intrinsic value of $7.6 and a manageable debt-to-equity ratio 20.7% position Nokia as a value-oriented pick in the evolving telecom landscape.
Key Catalysts
- Global 5G rollout and network modernization.
- Strategic partnerships with major telecom operators.
- Cost optimization initiatives improving margins.
Risk Factors
- Intense competition from Ericsson, Huawei, and new entrants.
- Currency fluctuations impacting euro-denominated revenues.
- Lower ROIC 5.5% compared to sector peers.
ResMed Inc. (RMD)
| Metric | Value |
|---|---|
| Market Cap | $36.2B |
| Quality Rating | 7.4 |
| Intrinsic Value | $247.4 |
| 1Y Return | 2.3% |
| Revenue | $5,257.4M |
| Free Cash Flow | $1,767.2M |
| Revenue Growth | 9.4% |
| FCF margin | 33.6% |
| Gross margin | 60.1% |
| ROIC | 24.8% |
| Total Debt to Equity | 13.8% |
Investment Thesis
ResMed is a global leader in digital health and respiratory care, with a $36.2B market cap and a 7.4 quality rating. The company’s $5.26B revenue and $1.77B free cash flow are supported by a 9.4% revenue growth rate and a 33.6% FCF margin. With a 60.1% gross margin and 24.8% ROIC, ResMed demonstrates strong profitability and capital efficiency. Its intrinsic value of $247.4 highlights potential undervaluation in the healthcare sector.
Key Catalysts
- Rising prevalence of sleep apnea and chronic respiratory conditions.
- Expansion of digital health solutions and remote monitoring.
- Strong cash flow supporting innovation and acquisitions.
Risk Factors
- Regulatory changes in healthcare reimbursement.
- Competitive pressures from established medtech firms.
- Modest 1-year return 2.3% relative to sector averages.
First Solar, Inc. (FSLR)
| Metric | Value |
|---|---|
| Market Cap | $28.6B |
| Quality Rating | 7.3 |
| Intrinsic Value | $149.3 |
| 1Y Return | 37.3% |
| Revenue | $5,050.6M |
| Free Cash Flow | $614.5M |
| Revenue Growth | 31.2% |
| FCF margin | 12.2% |
| Gross margin | 40.0% |
| ROIC | 16.2% |
| Total Debt to Equity | 6.2% |
Investment Thesis
First Solar is a leader in advanced thin-film photovoltaic modules, with a $28.6B market cap and a 37.3% 1-year return. The company’s $5.05B revenue and $614.5M free cash flow are driven by a 31.2% revenue growth rate and a 40% gross margin. Its 16.2% ROIC and low debt-to-equity ratio 6.2% underscore financial strength. With an intrinsic value of $149.3, First Solar is well-positioned to benefit from the global shift toward renewable energy.
Key Catalysts
- Accelerating global adoption of solar energy.
- Strong project pipeline and technological innovation.
- Supportive policy environment for renewables.
Risk Factors
- Volatility in solar panel pricing and input costs.
- Competition from low-cost international manufacturers.
- Project execution and supply chain risks.
Natera, Inc. (NTRA)
| Metric | Value |
|---|---|
| Market Cap | $27.1B |
| Quality Rating | 6.1 |
| Intrinsic Value | $80.3 |
| 1Y Return | 64.5% |
| Revenue | $1,964.2M |
| Free Cash Flow | $104.6M |
| Revenue Growth | 44.4% |
| FCF margin | 5.3% |
| Gross margin | 62.9% |
| ROIC | (48.3%) |
| Total Debt to Equity | 15.7% |
Investment Thesis
Natera specializes in genetic testing and diagnostics, with a $27.1B market cap and a 64.5% 1-year return. The company’s $1.96B revenue and $104.6M free cash flow are propelled by a 44.4% revenue growth rate and a 62.9% gross margin. While the company’s ROIC is negative -48.3%, reflecting ongoing investment in R&D, its intrinsic value of $80.3 suggests long-term potential in precision medicine.
Key Catalysts
- Growing demand for non-invasive prenatal and oncology testing.
- Expansion into new diagnostic markets.
- Strong revenue growth and gross margins.
Risk Factors
- Ongoing operating losses and negative ROIC.
- Regulatory hurdles in genetic testing.
- High competition in the diagnostics sector.
NetApp, Inc. (NTAP)
| Metric | Value |
|---|---|
| Market Cap | $23.7B |
| Quality Rating | 6.9 |
| Intrinsic Value | $127.4 |
| 1Y Return | 2.6% |
| Revenue | $6,588.0M |
| Free Cash Flow | $1,658.0M |
| Revenue Growth | 3.3% |
| FCF margin | 25.2% |
| Gross margin | 70.0% |
| ROIC | 27.5% |
| Total Debt to Equity | 281.5% |
Investment Thesis
NetApp is a leader in hybrid cloud data management, with a $23.7B market cap and a 2.6% 1-year return. The company’s $6.59B revenue and $1.66B free cash flow are supported by a 3.3% revenue growth rate and a 70% gross margin. NetApp’s 27.5% ROIC and high debt-to-equity ratio 281.5% reflect both capital efficiency and leverage. Its intrinsic value of $127.4 indicates potential value in the data infrastructure space.
Key Catalysts
- Rising demand for cloud storage and data management.
- Expansion of hybrid and multi-cloud solutions.
- Strong profitability metrics.
Risk Factors
- High leverage increases financial risk.
- Intense competition from cloud hyperscalers.
- Modest revenue growth.
Insulet Corporation (PODD)
| Metric | Value |
|---|---|
| Market Cap | $22.0B |
| Quality Rating | 7.6 |
| Intrinsic Value | $103.4 |
| 1Y Return | 35.2% |
| Revenue | $2,188.2M |
| Free Cash Flow | $392.6M |
| Revenue Growth | 16.8% |
| FCF margin | 17.9% |
| Gross margin | 76.3% |
| ROIC | 22.4% |
| Total Debt to Equity | 96.9% |
Investment Thesis
Insulet is a pioneer in tubeless insulin pump technology, with a $22.0B market cap and a 35.2% 1-year return. The company’s $2.19B revenue and $392.6M free cash flow are driven by a 16.8% revenue growth rate and a 76.3% gross margin. With a 22.4% ROIC and a 7.6 quality rating, Insulet is well-positioned in the growing diabetes care market. Its intrinsic value of $103.4 suggests continued growth potential.
Key Catalysts
- Increasing global diabetes prevalence.
- Expansion of wearable medical devices.
- Strong gross margins and innovation pipeline.
Risk Factors
- High debt-to-equity ratio 96.9%.
- Regulatory and reimbursement risks.
- Competition from established medtech companies.
Waters Corporation (WAT)
| Metric | Value |
|---|---|
| Market Cap | $20.8B |
| Quality Rating | 6.3 |
| Intrinsic Value | $222.5 |
| 1Y Return | 8.2% |
| Revenue | $3,046.1M |
| Free Cash Flow | $619.4M |
| Revenue Growth | 5.9% |
| FCF margin | 20.3% |
| Gross margin | 58.6% |
| ROIC | 19.0% |
| Total Debt to Equity | 71.2% |
Investment Thesis
Waters is a leader in analytical instruments and laboratory solutions, with a $20.8B market cap and an 8.2% 1-year return. The company’s $3.05B revenue and $619.4M free cash flow are supported by a 5.9% revenue growth rate and a 58.6% gross margin. Waters’ 19% ROIC and a 6.3 quality rating reflect solid profitability and operational resilience. Its intrinsic value of $222.5 highlights potential in the life sciences sector.
Key Catalysts
- Rising demand for analytical testing in pharma and biotech.
- Expansion into emerging markets.
- Strong free cash flow generation.
Risk Factors
- Cyclical demand in end markets.
- High debt-to-equity ratio 71.2%.
- Competitive pressures from global instrument providers.
ON Semiconductor Corporation (ON)
| Metric | Value |
|---|---|
| Market Cap | $20.8B |
| Quality Rating | 7.1 |
| Intrinsic Value | $78.8 |
| 1Y Return | -29.0% |
| Revenue | $6,398.8M |
| Free Cash Flow | $1,515.0M |
| Revenue Growth | (17.9%) |
| FCF margin | 23.7% |
| Gross margin | 37.6% |
| ROIC | 12.1% |
| Total Debt to Equity | 42.4% |
Investment Thesis
ON Semiconductor is a key supplier of intelligent power and sensing solutions, with a $20.8B market cap and a -29.0% 1-year return. The company’s $6.40B revenue and $1.52B free cash flow are offset by a -17.9% revenue growth rate, reflecting recent industry headwinds. However, a 23.7% FCF margin and 12.1% ROIC demonstrate underlying operational strength. Its intrinsic value of $78.8 suggests potential for recovery as demand for automotive and industrial chips rebounds.
Key Catalysts
- Growth in electric vehicles and industrial automation.
- Expansion of power management solutions.
- Strong free cash flow margins.
Risk Factors
- Recent revenue contraction and negative 1-year return.
- Cyclical semiconductor market dynamics.
- Moderate debt-to-equity ratio 42.4%.
Portfolio Diversification Insights
This watchlist spans technology, healthcare, and renewable energy, offering exposure to both growth and defensive sectors. Technology stocks (ASML, Ubiquiti, NetApp, ON Semiconductor, Nokia) provide innovation-driven upside, while healthcare (ResMed, Insulet, Natera, Waters) adds resilience and demographic tailwinds. First Solar introduces a sustainability angle, balancing the portfolio against sector-specific risks and enhancing overall diversification.
Market Timing & Entry Strategies
Given the varied sector exposures, consider phased entry strategies such as dollar-cost averaging to mitigate volatility. Monitor sector rotation trends and macroeconomic indicators—technology and healthcare may benefit from continued innovation cycles, while renewable energy could see momentum from policy shifts. Use ValueSense’s intrinsic value tools to identify optimal entry points based on valuation gaps and quality ratings[1][2].
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected?
Stocks were chosen using ValueSense’s proprietary screening tools, focusing on intrinsic value, quality ratings, sector diversification, and key financial metrics such as revenue growth, free cash flow, and ROIC[1][2].
Q2: What's the best stock from this list?
The “best” stock depends on individual investment goals, but ASML and Ubiquiti stand out for their strong growth, high quality ratings, and sector leadership. Each stock’s analysis provides context for its unique strengths.
Q3: Should I buy all these stocks or diversify?
Diversification is a key principle in portfolio construction. This watchlist is designed to provide exposure across multiple sectors, reducing risk associated with any single company or industry.
Q4: What are the biggest risks with these picks?
Risks include sector-specific headwinds, market volatility, regulatory changes, and company-specific challenges such as high leverage or negative ROIC. Each stock’s section details its primary risk factors.
Q5: When is the best time to invest in these stocks?
Optimal timing varies by stock and market conditions. ValueSense’s intrinsic value and quality ratings can help identify attractive entry points, while dollar-cost averaging can reduce timing risk[1][2].